PCI Pharma Services announces Bellwyck acquisition
PCI Pharma Services has bought Toronto-based packaging and labelling specialist Bellwyck Pharma Services, adding four GMP-compliant facilities in the US, Germany and Canada to its global network, the CDMO announced Tuesday.
Bellwyck’s supply chain offering includes clinical trial packaging, labeling and logistics for Phase I-IV studies and commercial packaging.
“We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities,” said Salim Haffar, chief executive officer, PCI Pharma Services.
With the addition of Bellwyck, PCI will now feature 25 GMP facilities across North America, Europe, and Asia-Pacific, employing over 3,700 people.
The Bellwyck acquisition marks PCI’s third acquisition outside of the US in three years.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance